Imugene Entered into a Clinical Trial Supply Agreement with Roche to Evaluate PD1-Vaxx + Atezolizumab for the Treatment of Lung Cancer
Shots:
- The companies collaborated to evaluate Imugene’s PD1-Vaxx (B-cell activating immunotherapy) + atezolizumab (immune checkpoint inhibitor targeting PD-L1) in P-Ib trial in patients with NSCLC at sites in USA & Australia
- The objectives of the P-1b dose escalation/expansion trial is to determine safety, efficacy & optimal dose of PD1-Vaxx + atezolizumab as 1L therapy in ICI treatment naïve NSCLC patients or ICI pretreated patients
- Imugene will be the sponsor of study & will fund the clinical study while Roche will supply atezolizumab. Additionally, the therapy also has approved in four indications in advanced NSCLC as monothx. or in combination with targeted therapies & CT
Ref: Imugene | Image: Roche
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com